| Background: Gliomas are glial neoplasms developing from neuroepi dermal layer cells. Shown by domestic statitics, gliomas are the leading group of the primary central nervous system tumors, accounting for 35.12 -61. 10% , average 49.17%, of all primary brain tumors. For the difficulties in its early diagnosis and surgical removal of all residue diseased tissues, besides its highly Invasive capacity, rapid progression, and frequent reoccurrence, the most glioma represents an extremely life-threatening intracranial malignant tumor. Owing to the progress in molecular biology, new methods can be applied to analysis the pathogenesis and to multimodality therapy in gliomas.The 14-3-3σ (sigma) protein, a negative regulator of the cell cycle, is a human mammary epithelium-specific marker that is downregulated in transformed mammary carcinoma cells. It has also been identified as a factor led to stabilized expression of p53 involved in cell cycle checkpoint control after DNA damage. Decreased expression of 14-3-3σ was recently reported in several types of carcinomas, further suggesting that the negative regulatory role of 14-3-3σ in the cell cycle is compromised during tumorigenesis. Hypermethylation of CpG islands in the σ gene promoter plays key role in the negative expression of 14-3-3σ . However, the relationship between hypermethylation of CpG islands in the σ gene promoter and tumorigenesis in gliomas remains unclear.Purpose:To investigate the occurrence of hypermethylation of CpG sites in promoter regions of 14-3-3σ in gliomas. To analyze the relationship between the incidence rate and WHO grading. To investigate its effect in tumorigenesis.Methods: All the experiments is devided into 4 groups according its WHO grading. The expression of p53 and MDM2 is evaluated by Spimmunohisto-... |
PDF Full Text Request